Pharmacogenetic tests in psychiatry

American Journal of Psychiatry

Volumn 175, Issue 2, 2018, Pages 189-

  Bousman, Chad ^a,b   Allen, Josiah ^c,d   Eyre, Harris A ^e,f  

^a UNIVERSITY OF CALGARY   (Canada)

^b Medigenics Consulting   (United States)

^c EAST TEXAS MEDICAL CENTER   (United States)

^d DEAKIN UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

DRD2 GENE; DRUG GENE INTERACTION; DRUG RESPONSE; EVIDENCE BASED MEDICINE; GENE; GENE INTERACTION; LETTER; MEDICAL EDUCATION; PHARMACOGENETIC TESTING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRY; STANDARDIZATION; UNITED STATES; HUMAN; MENTAL DISEASE; PHARMACOGENETICS;

HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHIATRY;

EID: 85041640970     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.17101086     Document Type: Letter

References (5)

1. Rahman T, Ash DM, Lauriello J, et al: Misleading guidance from pharmacogenomic testing. Am J Psychiatry 2017;174:922-924
2. Bousman CA, Hopwood M: Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 2016;3:585-590
3. Singh AB: Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci 2015;13:150-156
4. Pérez V, Salavert A, Espadaler J, et al: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 2017;17:250
5. Bradley P, Shiekh M, Mehra V, et al: Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res 2017;96:100-107